ArticleInternational journal of clinical and experimental medicine2015
Clinical analysis of tumor and non-tumor patients complicated with pulmonary embolism.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Clinical features of pulmonary embolism in patients with lung cancer: A meta-analysis.PloS one · 2019Pooled it
- Clinical value of measuring plasma D-dimer levels in patients with esophageal cancer.Journal of cardiothoracic surgery · 2024Article
- Primary pulmonary intravascular large B‑cell lymphoma misdiagnosed as pneumonia: Four case reports and a literature review.Oncology letters · 2023Article
- Differential clinical manifestations and clinical outcome of cancer-related pulmonary embolism.The Korean journal of internal medicine · 2020Article
- Values of thoracic contrast-enhanced computed tomography in detecting incidental pulmonary thromboembolism in patients with malignant tumors.Oncology letters · 2019Article
- Lung Cancer and Pulmonary Embolism: What Is the Relationship? A Review.Journal of Cancer · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze the differences of the clinical characteristics and risk factors between tumor and non-tumor patients complicated with pulmonary embolism.
methodsA retrospective analysis was conducted on 96 hospitalized patients complicated with pulmonary embolism admitted into 307 Hospital of PLA from January 2009 to December 2014. 96 cases were divided into tumor group (n=52) and non-tumor group (n=44) according to whether they were accompanied with malignant tumors. The relevant characteristics of tumor group, comparison of the risk factors and laboratory results between two groups were assessed.
resultsLung cancer was prone to pulmonary embolism in malignant tumors and adenocarcinoma was the commonest pathological type. 31 (59.6%) cases developed pulmonary embolism within 3 months after tumor was diagnosed. The level of serum D-dimer and leukemia in tumor group were higher than that in non-tumor group (3241.06±4514.16 μg/L vs 1238.49±1236.69 μg/L and 9.68±5.53×10(9)/L vs 7.90±3.84×10(9)/L), with a significant statistical difference (P=0.004 and 0.015). The level of serum platlet in tumor group were lower than that in non-tumor group (204.63±132.58×10(9)/L vs 222.26±76.92×10(9)/L), with a significant statistical difference (P=0.023). Coronary heart disease, chronic lung disease, diabetes, hyperlipemia and cerebral infarction were significantly different between two groups (P<0.01). Unexplained dyspnea (51/96, 53.1%) was the main symptom of pulmonary embolism, yet no significant difference was found between the two groups. 33 cases (34.4%) combined with deep venous thrombosis of lower limb, right lower limb more than the left. Right main pulmonary artery and its branches embolism were seen in 46 cases (47.9%) according to imaging examination, and no significant difference between two groups. After thrombolytic and anticoagulant therapy, only 9 cases died of Pulmonary embolism.
conclusionThere is no obvious and significant difference in clinical symptoms between tumor and non-tumor patients complicated with pulmonary embolism. Using of anticoagulant and thrombolytic therapy can obtain good curative effect upon diagnosis.
Indexed as
Identifiers
26770488PMC4694388W2410895571What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.